文献速递痛风与晶体性关节病

维立奴拉联合别嘌醇在痛风成人中的药效学、药代动力学及安全性:一项IIa期开放标签研究

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study.
PubMed 文献 · RMD Open · 2018-02-08

这项IIa期开放标签研究将41例痛风患者随机纳入维立奴拉(2.5-20 mg)联合别嘌醇(300 mg每日一次)与别嘌醇单药(300 mg每日一次、600 mg每日一次或300 mg每日两次)比较,每治疗期7天。结果显示联合治疗呈剂量依赖性降低血清尿酸,最大降幅为47%-74%,而别嘌醇单药为40%-54%;联合治疗耐受性良好,无严重不良事件。

要点

  • 维立奴拉联合别嘌醇降低血清尿酸呈剂量依赖性,最大降幅47%-74%。
  • 别嘌醇单药300 mg每日一次、600 mg每日一次和300 mg每日两次的最大降幅分别为40%、54%和54%。
  • 联合治疗耐受性良好,无严重不良事件、无因不良事件退出、无肾脏相关事件。

核心结论

  • 维立奴拉与别嘌醇联合给药产生剂量依赖性的血清尿酸降低。
  • 所有维立奴拉与别嘌醇剂量组合总体耐受性良好。
  • 这些数据支持继续研究口服维立奴拉用于痛风患者。

研究设计与样本

  • IIa期、开放标签研究,41例痛风成人随机纳入两个队列。
  • 比较维立奴拉(2.5-20 mg)联合别嘌醇(300 mg每日一次)与别嘌醇单药(300 mg每日一次、600 mg每日一次或300 mg每日两次)。
  • 每个治疗期为7天,系列采集血浆/血清和尿液样本检测维立奴拉、别嘌醇、奥昔嘌醇和尿酸。

主要发现

  • 合并队列的血清药效学数据显示,维立奴拉联合别嘌醇治疗后7-12小时血清尿酸较基线最大降幅(Emax)达峰值。
  • 联合治疗呈剂量依赖性降低血清尿酸:维立奴拉2.5、5、7.5、10、15和20 mg联合别嘌醇300 mg每日一次的最小二乘均值Emax分别为47%、59%、60%、67%、68%和74%。
  • 别嘌醇单药300 mg每日一次、600 mg每日一次和300 mg每日两次的Emax分别为40%、54%和54%。
  • 维立奴拉对别嘌醇血浆药代动力学无影响,但使奥昔嘌醇Cmax降低19.0%-32.4%,使血浆浓度-时间曲线下面积(从零时至最后可测时间点)降低20.8%-39.2%。
  • 维立奴拉联合别嘌醇耐受性良好,无严重不良事件、无因不良事件退出、无肾脏相关事件;实验室值无临床意义变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Verinurad (RDEA3170) is a high affinity, selective uric acid transporter (URAT1) inhibitor indevelopment for treating gout and asymptomatic hyperuricaemia. This phase IIa study evaluated the pharmacodynamics, pharmacokinetics and safety of verinurad combined with allopurinol versus allopurinol alone in adults with gout. METHODS: Forty-one subjects were randomised into two cohorts of verinurad (2.5-20 mg) plus allopurinol (300 mg once daily) versus allopurinol 300 mg once daily, 600 mg once daily or 300 mg twice daily alone. Each treatment period was 7 days. Serial plasma/serum and urine samples were assayed for verinurad, allopurinol, oxypurinol and uric acid. RESULTS: Serum pharmacodynamic data pooled across cohorts demonstrated maximum per cent decreases in serum urate (sUA) from baseline (Emax) at 7-12 hours after verinurad plus allopurinol treatment. Combination treatment decreased sUA in dose-dependent manner: least-squares means Emax was 47%, 59%, 60%, 67%, 68% and 74% for verinurad doses 2.5, 5, 7.5, 10, 15 and 20 mg plus allopurinol 300 mg once daily, versus 40%, 54% and 54% for allopurinol 300 mg once daily, 600 mg once daily and 300 mg twice daily. Verinurad had no effect on allopurinol plasma pharmacokinetics, but decreased oxypurinol Cmax by 19.0%-32.4% and area under the plasma concentration-time curve from time zero to the last measurable time point by 20.8%-39.2%. Verinurad plus allopurinol was well tolerated with no serious adverse events (AEs), AE-related withdrawals or renal-related events. Laboratory values showed no clinically meaningful changes. CONCLUSION: Verinurad coadministered with allopurinol produced dose-dependent decreases in sUA. All dose combinations of verinurad and allopurinol were generally well tolerated. These data support continued investigation of oral verinurad in patients with gout. TRIAL REGISTRATION NUMBER: NCT02498652.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Fleischmann R, Winkle P, Miner JN, et al. Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study. RMD Open. 2018. PMID: 29531784. doi:10.1136/rmdopen-2017-000584

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。